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Abstract
Background and Purpose: Stereotactic body radiotherapy (SBRT) for lung cancer accompanies a
non-negligible risk of radiation pneumonitis (RP). This study presents a Bayesian network (BN)
model that connects biological, dosimetric, and clinical RP risk factors.
Material and Methods: 43 non-small-cell lung cancer patients treated with SBRT with 5 fractions or
less were studied. Candidate RP risk factors included dose-volume parameters, previously reported
clinical RP factors, 6 protein biomarkers at baseline and 6 weeks post-treatment. A BN ensemble
model was built from a subset of the variables in a training cohort (N=32), and further tested in
an independent validation cohort (N=11).
Results: Key factors identified in the BN ensemble for predicting RP risk were ipsilateral V5, lung
volume receiving more than 105% of prescription, and decrease in angiotensin converting enzyme
(ACE) from baseline to 6 weeks. External validation of the BN ensemble model yielded an area
under the curve of 0.8.
Conclusions: The BN model identified potential key players in SBRT-induced RP such as high
dose spillage in lung and changes in ACE expression levels. Predictive potential of the model is
promising due to its probabilistic characteristics.
Keywords: radiation pneumonitis, stereotactic body radiotherapy, biomarkers, ensemble method,
Bayesian network
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1. Introduction
In recent years, stereotactic body radiotherapy (SBRT) has become the treatment of choice
for non-operable early stage non-small cell lung cancer (NSCLC), demonstrating a local control
rate close to 90% [1]. Incidence of pulmonary toxicity, usually defined as symptomatic radiation
pneumonitis (RP), is reported to be less than 10% [2] due to focused radiation to a small target which
spares large volume of healthy lung [3]. However, several non-dosimetric factors reportedly increase
or decrease the RP risk, such as central tumor location [4], baseline interstitial pneumonitis [5]
and chronic obstructive pulmonary disease (COPD) [6]. Ignoring these factors could underestimate
RP risk for certain patients. Thus, there is a clinical need to augment dosimetric RP models with
patient-specific clinical and biological risk modifiers towards more patient-specific predictions.
We propose Bayesian network (BN) as a multivariate modeling platform to accommodate such
high-dimensional data. BN can be characterized as graphical representation of relationships between
input variables called a directed acyclic graph (DAG). Variables in a DAG are connected along the
direction of influence. This allows us to study such a radiobiological system as a "whole" whereas
conventional multivariate models such as logistic regression are limited to the predictive value of
variables in a model [7]. The BN approach has been adopted by a number of outcome studies [8] [9]
[10], and specifically for radiation pneumonitis from conventional fractionation [11] where finding a
consensus of prediction results from several BN models (ensemble approach) was shown to improve
RP prediction. However, the BN approach has not been applied to SBRT cases where dose-volume
metrics and biological damage relationships are still not well understood.
The aim of this study is to develop a Bayesian Network RP model for NSCLC SBRT patients.
While a primary objective is to assess its predictive potential, we will also address its ability to
uncover underlying radiobiological relationships and generate new hypotheses.
2. Materials and Methods
2.1. Patient cohort
Forty three stage I and II NSCLC patients were recruited for this study prospectively from
three institutions upon approval of respective ethics review boards: McGill University Health Centre
(MUHC), Centre Hospitalier de l’Université de Montréal (CHUM), andWashington University in St.
Louis (WashU), 32 patients from MUHC and CHUM formed the training cohort for BN modeling.
2
11 patients from WashU were reserved for model validation. Every patient met the following
eligibility criteria: 1) received SBRT of equal or less than 5 fractions with curative intent, 2) no
history of previous lung irradiation, and 3) baseline Karnofsky performance status ≥ 70. Detailed
cohort characteristics are summarized in table 1. The patients were treated with radiotherapy (RT)
without any adjuvant treatment. Depending on institutions, three different delivery techniques were
used: 3-dimensional (3D) conformal radiotherapy, RapidArc™(Varian Medical Systems, Palo Alto,
CA) Volumetric Arc Therapy (VMAT), and CyberKnife (Accuray Inc, Sunnyvale, CA). Detailed
RT procedures are provided in supplementary tables 1 and 2.
2.2. Data collection
Blood samples from the patients were first acquired on the CT simulation day as a baseline and
at 6 weeks post-treatment. Enzyme-linked immunosorbent assay (ELISA) was used for measuring
biomarker concentrations in the samples. Incidence rate of symptomatic RP, classified as Common
Toxicity Criteria for adverse events (CTCAE) toxicity (version 4) grade 2 or higher, was 13% (4/32)
in the training and 9% (1/11) in the validation cohort. Median follow-up was 12 and 34 months for
the training and validation cohorts, respectively.
2.3. Candidate variables
Candidate variables for the BN pneumonitis model were chosen from 3 main categories: bio-
logical, dosimetric and clinical variables. Candidate biological variables consisted of serum con-
centration of interleukin(IL)-6, IL-8, angiotensin converting enzyme (ACE), alpha-2-macroglobulin
(α2M) , and transforming growth factor (TGF)-β1 and plasma concentration of osteopontin (OPN).
As summarized in [12], these biomarkers represent different biological processes involved in patho-
genesis of radiation-induced lung injury, such as pro-(IL-6 [13], OPN [14]) and anti-(IL-8 [15])
inflammatory reactions, fibrogenesis (TGFβ [16]), vascular damage (ACE [17]) and modulation of
inflammatory reactions (α2M [18]). 12 features in total were extracted (6 biomarkers x 2 time
points). The biomarker features at 6-weeks were calculated as percentage difference from respective
baseline levels. The following 7 clinical RP risk factors were chosen by literature survey: super-
oinferior PTV location (PTVCOMSI) [19], age [20], smoking status [21], COPD [6], ACE inhibitor
[22], baseline interstitial lung disease [5], and centrally located tumours [4]. Dosimetric factors
were derived from planned dose converted to equivalent dose in 2 Gy fraction (EQD2) using an
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Table 1: Characteristics of the training and validation cohorts. *Calculated for whole lung subtracted from planning
target volume and converted to equivalent dose in 2 Gy fraction (EQD2).
Patient count (%)
Training Validation
Cohort size 32 11
Tumor stage
I 32 (100) 9 (81)
II 0 (0) 2 (19)
RP grades
0 17 (53) 0 (0)
1 11 (34) 10 (91)
2 2 (6) 0 (0)
3 2 (6) 1 (9)
≥ 4 0 (0) 0 (0)
≥ 2 4 (13) 1 (9)
Mean lung dose*
median 4.9 6.3
range 2.4-10.9 1.2-9.9
RT modality
3D conformal 19 (59) 11 (100)
VMAT 5 (16) 0 (0)
CyberKnife 8 (25) 0 (0)
RT prescription
60 Gy in 3 fractions 8 (25) 0 (0)
60 Gy in 5 fractions 5 (16) 1 (9)
50 Gy in 5 fractions 4 (13) 4 (36)
48 Gy in 3 fractions 12 (38) 0 (0)
34 Gy in 1 fractions 3 (9) 0 (0)
54 Gy in 3 fractions 0 (0) 5 (45)
55 Gy in 5 fractions 0 (0) 1 (9)
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alpha-beta ratio of 4 Gy for lung [23] and 2 Gy for heart [24]. For lung dose calculation, PTV
was subtracted from contoured lung. Mean lung dose (MLD) and various Vx values (lung volume
receiving > x Gy) for ipsilateral and whole lung were estimated. Due to high correlation between
these parameters [25], exploratory analysis was performed to find the smallest number of features
that can capture dose heterogeneity relevant to RP. In this analysis, Vx was computed at various
threshold dose x in three different ways: 1) x as an absolute dose or relative to prescription dose, 2)
Vx normalized to lung volume or as a absolute volume, and 3) ipsilateral or whole lung. In addition
to lung dose, we also considered mean heart dose (MHD) [26], fraction size [27], and PTV volume
[28].
2.4. Bayesian Network training
A Bayesian network ensemble model was trained from the candidate variables following the
methods developed in [11]. In brief, the training was done in 4 steps:
1. Data discretization: Every continuous variable was discretized into 2 bins at a boundary that
maximizes mutual information with respect to RP, as shown in supplementary table 3.
2. Feature selection with the Koller-Sahami (KS) filter: The number of candidate variables were
reduced to the smallest subset that maximized explanatory power measured by cross-entropy
with respect to RP.
3. DAG training: Posterior distribution of Bayesian network graphs was obtained by Markov-
Chain Monte Carlo sampling under causality constraints between variables.
4. Parameter learning: Every variable in a BN is treated as a probabilistic distribution which
is conditioned upon its upstream variables ("parents"). BN parameters, referred to as con-
ditional probability values for every pair of a node and its parents, were learned from data
using the expectation-maximization algorithm.
2.5. BN model testing
The trained BN ensemble model derived probability of RP using known input variables. Clas-
sification of RP events was made by thresholding the RP probabilities. Classification performance
was measured using three receiver operating characteristics (ROC) metrics: area under the curve
(AUC), sensitivity, and specificity at the optimal operating threshold maximizing the sum of sensi-
tivity and specificity. Model statistical testing was carried out in two ways: 1) the .632+ bootstrap
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Figure 1: Odds ratios of lung Vx measured at various threshold dose values (x), normalization schemes, and lung
volume definition.
method [29]: the training was repeated in 200 replicates which were resampled from the original
data with replacement where the instances that were not sampled into the replicates were used for
testing. 2) the final model was trained using the entire training set and tested in the validation
cohort.
3. Results
3.1. Exploratory analysis of lung DVH parameters
Correlation between lung Vx and RP was examined by the change in odds ratios at various
threshold dose (x) (figure 1). When x was used as absolute dose, highest odds ratio (5.685) was
marked at 5 Gy for ipsilateral lung. When the percentage of a prescription dose was used as x,
increase in correlation was observed in high dose regions beyond 50% of the prescription dose.
Guided by this analysis, we chose two Vx parameters that represent low and high dose spillage in
this order: percentage of ipsilateral lung volume receiving 5 Gy or more (V5) and absolute lung
volume receiving more than 105% of prescription dose (V105%). In a similar fashion, ipsilateral
MLD (odds ratio: 2.400) was preferred over MLD for the whole lung (odds ratio: 2.365).
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3.2. Variable selection and the Bayesian Network ensemble model
The KS filter reduced the candidate (dosimetric, biological, and clinical) variables from 25 into
the following 6 (supplementary table 3): 1) pre-treatment OPN, 2) 6 weeks ACE, 3) pre-treatment
TGFβ, 4) ipsilateral V5, 5) V105%, and 6) PTVCOMSI. Inter-relationships between these variables
and RP were established in the BN graphs. Bootstrap testing on BN graph learning detected 11
statistically significant links out of possible 19 from an ensemble of 50 graphs where bootstrapped
RP prediction performance achieved optimality (figure 3). A mean confidence level of the significant
links was 0.57, while the upper bound of random variation was estimated to be 0.29 [30].
3.3. Prediction performance of the BN model
When bootstrap validation was used, RP prediction improved upon increasing number of graphs
in an ensemble (figure 3). Optimal performance was achieved at an ensemble size of 50 where AUC,
sensitivity and specificity were 0.99, 1, and 0.98, respectively. At the optimal classification threshold,
sensitivity was consistently higher than specificity. In external validation, AUC was the highest (0.8)
at ensemble sizes 5-30. The BN model was subsequently tested using only the information available
at baseline i.e. without ACE at 6 weeks. As a result, AUC and sensitivity decreased significantly
at all ensemble sizes. In the validation cohort, however, slightly better performance was observed
with only baseline information.
4. Discussion
Events of RP from lung SBRT are rare and identifying the susceptible patients before radio-
therapy remains a difficult task, with conflicting results between studies. This study intended to
objectively select and combine RP risk factors into a Bayesian Network and test its predictive
power. Two factors account for good bootstrap performance of the resulting model in the training
cohort. First, the main driving force was strong individual predictive power of the key variables
in the model. Univariate AUC values of ACE at 6 weeks, V5, and V105%, 3 variables connected
to RP with high confidence, were respectively 0.94, 0.85 and 0.96 in the training cohort. Another
factor was the use of an ensemble instead of a single model, which improved performance both in
training and validation cohorts. Predictive benefit of an ensemble approach was already shown by
other outcome studies [11] [31].
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Figure 2: Variables connected by significant associations detected in an ensemble of 50 graphs. Edge thickness was
drawn proportionally to bootstrap estimated confidence level. Arrow-headed and bar-headed edges are assigned to
positive and negative correlations, respectively. ipsi: ipsilateral lung, _pre: baseline biomarker levels
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Figure 3: Classification performance of the Bayesian Network model in two cohorts with varying ensemble size. Error
bars: bootstrap-estimated 95% confidence intervals.
Amongst the biomarkers we studied, we found lower concentration of ACE at 6 weeks was
strongly associated with RP events. This result is in line with investigation by Zhao et al. [16] who
reported lower ACE level at baseline and mid-treatment for patients with RP grade ≥ 2. In the
Bayesian network ensemble the ACE was connected to dosimetric variables with high confidence.
Causality of this relationship could be inferred from the knowledge that the main secretion site
of ACE happens in lung epithelium and external stress to pulmonary vasculature such as ionizing
radiation or Bleomycin exposure decreases serum ACE [17]. The use of ACE inhibitors at baseline,
however, was not a significant predictor of RP (p = 0.64) indicating that direct measurement of
ACE expression could be a more sensitive test to predict RP.
Choice of 6 weeks as a time point to gauge post-treatment biomarker response was adequate
to predict late toxicity before it happened, as the earliest occurrence of RP was 94 days post-RT.
However, such information would not be available for the treatment planning stage inn such a case.
We tested this scenario by attempting prediction with masked ACE values where the BN model can
cope with missing information by marginalizing probability distribution over unknown variables.
The role of ACE was not clearly shown in our external validation cohort where the absence of
such information did not reduce performance. Although these issues need to be confirmed in larger
trial, our model predictions with post-RT variables may aid in monitoring high-risk patients or in
prescribing anti-inflammatory medications.
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We also observed that the size of high dose spillage, represented by lung volume outside PTV
receiving dose > 105%, was predictive of RP in univariate analysis and also one of the key variables
in the BN model. This "high dose effect" on RP has been previously reported by a number of
studies [19] [32]. Our results on exploratory analysis on Vx point out that both low-dose (V5) and
high dose components might be relevant to RP. Previous lung SBRT protocols including RTOG
0236 and 0813 stipulate this volume as one of the quality assurance metrics to be regulated, setting
its upper limit on 15% of the PTV volume. Further studies may be needed to clarify the effects of
smaller volume of high dose irradiation to lung leading to RP onset.
The main limitation of the current study is the low number of toxicity events in the evaluated
cohorts, which led to relatively low specificity of the optimized model. Nevertheless, our computa-
tional approach reduced the data dimensionality and identified key variables that may mitigate the
impact of a low event rate on fitting. Also, the links that we discovered in the BN graphs represent
influential effects among variables that is not necessarily causal always. However, such knowledge
may help provide new insights and guide generating new data-driven hypotheses.
5. Conclusion
We developed a Bayesian Network ensemble for modeling radiation pneumonitis after lung
SBRT. The process of building the model and the resulting model structure identified potential
key players in predicting RP in NSCLC SBRT patients such as high dose spillage to the lung and
changes in post-treatment ACE expression levels. This probabilistic model can potentially provide
new insights into RP onset and help guide designing new studies as the interest of expanding SBRT
to higher risk populations continues to grow.
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Supplemental Materials for: Modeling of Radiation Pneumonitis after
Lung Stereotactic Body Radiotherapy: A Bayesian Network Approach
1
Table 1: Detailed radiotherapy procedures used for the training cohort. GTV: gross tumour volume, ITV: internal target volume, IGTV: internal gross tumour volume, PTV: planning
target volume, Tx: prescription dose, 4DCT: 4-dimensional computed tomography, IGRT: image-guided radiotherapy, fx: fraction, MU: monitoring unit.
Institution MUHC CHUM
Technique 3D-CRT VMAT CyberKnife
Dose prescription Dose normalized to 100 % at Tx, 95% of
PTV receives Tx or higher (D95% ≥ Tx)
Dose normalized to 100 % at Tx which covers 95% or more of the PTV
Dose planning procedure/
calculation algorithm
Forward planning using Eclipse (Var-
ian, USA)/ superposition-convolution al-
gorithm with heterogeneity correction
Inverse planning with RapidArc (Var-
ian, USA)/ superposition-convolution al-
gorithm with heterogeneity correction
Inverse planning with Multiplan (Accuray,
USA) / Monte Carlo calculation
Beam type 6 MV photon 6 MV photon 6 MV photon
Target volume definition ITV: drawn from 4DCT using maximum
intensity projection
PTV: ITV + 5 mm margin
IGTV: drawn on extreme phases of 4DCT
to represent its full extent
PTV: IGTV + 5 mm margin
GTV: drawn on breath hold, corrected if
needed for deformation/rotation using ex-
treme phases
PTV: GTV + 5 mm margin
Dose fractionation 50 Gy in 5 fx: tumor at central loca-
tion and/or close to critical organs (chest
wall/large vessels/spinal cord)
34 Gy in 1 fx: otherwise, upon patients’
request for shorter treatment
48 Gy in 3 fx: otherwise
50 Gy in 5 fx: tumour at central location
60 Gy in 5 fx: peripheral tumour close to OARs
60 Gy in 3 fx: otherwise
Dose constraints to OARs 50 Gy in 5 fx: RTOG 0915
48 Gy in 3 fx: RTOG 0915
34 Gy in 1 fx: RTOG 0813
Timmerman et al. [S33]
Immobilization BodyFix (Elekta Oncology, Norcross, GA) BodyFix (Elekta Oncology) Vac-Lok (Civco Medical Solutions, Orange
City, IA)
IGRT CBCT at every fraction Pre- and mid-treatment CBCT at every
fraction
Real-time target tracking
Plan verification Independent MU check Independent MU check, daily dynalog ver-
ification
Independent MU check
2
Table 2: Detailed radiotherapy procedures used for the validation cohort.
Institution WashU
Technique 3D-CRT
Dose prescription Dose generally prescribed to 80% isodose line (range 60-
90%) and covers >95% of PTV
Dose planning procedure/
calculation algorithm
Forward planning with 7-11 non-coplanar beams using Pin-
nacle (Philips, Netherlands)/ superposition-convolution al-
gorithm with heterogeneity corrections
Beam type 6 MV photons
Target volume definition ITV: drawn from 4DCT using maximum intensity projec-
tion
PTV: ITV + 5 mm margin
Dose fractionation 50-60 Gy in 5 fx: central location or close to critical organs
54 Gy in 3 fx: all others
Dose constraints to OARs 50-60 Gy in 5 fx: RTOG 0813
54 Gy in 3 fx: RTOG 0618
Immobilization Abdominal compression (CDR systems, Canada)
IGRT CBCT at every fraction with KV fluoroscopy
Plan verification Independent MU check
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Table 3: Odds ratios of candidate variables, bin boundary used for discretization, and frequency of selection obtained
by bootstrapping the KS variable filtering. P-values were adjusted for multiple comparison using a method by
Benjamini and Hochberg [S34]. *variables selected for the BN modeling stage. † taken as a percentage change from
baseline.
Odds ratio (p-value) Bin boundary Selection frequency
Biological variables
OPN (baseline)* 0.887 (0.886) 54.2 ng/ml 0.394
OPN (6 weeks†) 1.150 (0.886) 80.9 % 0.133
IL8 (baseline) 2.862 (0.210) 31.0 pg/ml 0.228
IL8 (6 weeks) 0.404 (0.637) -60.4 % 0.264
ACE (baseline) 1.999 (0.529) 141.1 ng/ml 0.308
ACE (6 weeks)* 0.002 (0.010) -15.8 % 0.782
IL6 (baseline) 0.070 (0.657) 7.0 pg/ml 0.2
IL6 (6 weeks) 1.106 (0.886) -7.0 (%) 0.058
a2M (baseline) 0.553 (0.638) 5.3 mg/ml 0.328
a2M (6 weeks) 0.848 (0.886) -7.6 % 0.142
TGFb (baseline)* 1.866 (0.540) 42.2 ng/ml 0.504
TGFb (6 weeks) 0.493 (0.610) 1.4 % 0.053
Dosimetric variables
MLD (ipsilateral) 2.400 (0.391) 13.8 Gy 0.107
V5 (ipsilateral)* 5.685 (0.060) 42.4 % 0.454
V105%* 5.848 (0.023) 1.4 cc 0.668
Fraction size 0.752 (0.886) 20 Gy per fraction 0.142
PTV volume 1.932 (0.518) 20.5 cc 0.064
MHD 1.945 (0.529) 9.0 Gy 0.153
Clinical variables
PTVCOMSI* 0.379 (0.391) 0.5 0.448
Age 1.172 (0.886) 69 0.121
Smoking 1.077 (0.945) 0.146
IP 1.300 (0.768) 0.061
Central tumour 1.800 (0.854) 0.068
COPD 0.750 (0.886) 0.120
ACE inhibitor 0.800 (0.638) 0.054
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